REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

07/02/2019 11:50

RNS Number : 3980P
Oxford Biomedica PLC
07 February 2019
 


 
 
 
 
 
 
Director Dealings / Market Share Transactions
 
Oxford, UK - 07 February 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, purchased 972 ordinary shares of 50p each ("Ordinary Shares") in the Company on 06 February 2019 on the London Stock Exchange at a price of 715p and sold 981 Ordinary Shares on 06 February 2019 on the London Stock Exchange at a price of 713p in order to transfer the shares into his ISA.
 
Following this purchase and sale Dr. Andrew Heath holds 43,977 shares representing 0.07% of the Company.
 
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold and purchased.
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Dr. Andrew Heath
 




 2.


Reason for the notification
 




 a.


Position/status


 Deputy Chairman and Senior Independent Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford BioMedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£7.15


972




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 972
 
 £7.15
 £6,949.80
 




f.


Date of the transaction


 2019-02-06
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Dr. Andrew Heath
 




 2.


Reason for the notification
 




 a.


Position/status


 Deputy Chairman and Senior Independent Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford BioMedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Disposal of ordinary shares
 




c.


Currency


 GBP - British Pound
 
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£7.13


981




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 981
 
 £7.13
 £6,994.53
 




f.


Date of the transaction


 2019-02-06
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 
The issued share capital of the Group is 66,122,617 ordinary 50p shares.                      
 
-Ends-
 



For further information, please contact:


 




 
Oxford BioMedica plc:
Stuart Paynter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
Notes for editors
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBBGDDISGBGCR